Insulin Lispro Protamine Suspension
DrugPatient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
Other names: Neutral Protamine Lispro (NPL), Humalog, ILPS
NCT Number: NCT00494013
The purpose of this study is to examine the effectiveness and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin therapy in adults with type 2 diabetes. A gatekeeper strategy will be employed for sequentially testing the secondary objectives.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
Other names: Neutral Protamine Lispro (NPL), Humalog, ILPS
Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
Time frame: Baseline, 24 Weeks
Time frame: Baseline, 12 Weeks, 24 Weeks
Time frame: 24 Weeks
Percentage of patients achieving Hemaglobin A1c (HbA1c) targets of less than 7.0% and less than or equal to 6.5% at endpoint.
Time frame: 24 Weeks
Glycemic variability was measured by standard deviation (SD) value of fasting blood glucose as measured by intra-patient glycemic variability (determined by the 7-point self-monitoring blood glucose [SMBG] profiles at endpoint) for the actual morning pre-meal blood glucose value.
Time frame: 24 Weeks
Actual daily mean blood glucose levels at endpoint.
Time frame: Baseline to 24 Weeks
Overall: any time after randomization. Hypoglycemic: any time patient experienced sign/symptom associated with hypoglycemia, or had old Roche blood glucose level <7 mg/dL. Nocturnal: any hypoglycemic event that occurred between bedtime and waking. Severe: event with symptoms consistent with neuroglycopenia in which patient requires assistance, and is associated with: a Roche blood glucose value <2.8 mmol/L or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Results are for the combined titration and maintenance periods.
Time frame: Baseline to 24 Weeks
Overall: any time after randomization. Hypoglycemic: any time patient experienced sign/symptom associated with hypoglycemia, or had old Roche blood glucose level <7 mg/dL. Nocturnal: any hypoglycemic event that occurred between bedtime and waking. Severe: event with symptoms consistent with neuroglycopenia in which patient requires assistance, and is associated with: a Roche blood glucose value <2.8 mmol/L or prompt recovery after oral carbohydrate, glucagon, or IV glucose. 1-year adjusted rate=(total number of episodes between 2 time intervals/number of days between intervals) X 365.25 days.
Time frame: Baseline to 24 Weeks
Overall: any time after randomization. Hypoglycemic: any time patient experienced sign/symptom associated with hypoglycemia, or had old Roche blood glucose level <7 mg/dL. Nocturnal: any hypoglycemic event that occurred between bedtime and waking. Severe: event with symptoms consistent with neuroglycopenia in which patient requires assistance, and is associated with: a Roche blood glucose value <2.8 mmol/L or prompt recovery after oral carbohydrate, glucagon, or IV glucose. 30-day adjusted rate=(total number of episodes between 2 time intervals/number of days between intervals) X 30 days.
Time frame: Baseline, 24 Weeks
Time frame: 24 Weeks
Insulin dose at endpoint was analyzed by 24-hour total daily insulin (units).
Time frame: 24 Weeks
Insulin dose at endpoint was analyzed by 24-hour total daily insulin per body weight (Units/kilograms).
Time frame: 24 Weeks
Eli Lilly and Company
Industry
Treat-to-Target Comparison of Two Basal Insulin Analogs (Insulin Lispro Protamine Suspension and Comparator) in Basal Therapy for Patients With Type 2 Diabetes Mellitus
Acronym: IOOY
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06638099
Diabetes, Diabetes Mellitus
El Centro, California, United States
View Trial DetailsNCT06769906
Behavior, Behavioral Symptoms
Seoul, South Korea
View Trial DetailsNCT06644651
Arterial Occlusive Diseases, Arteriosclerosis
Svendborg, Region Syddanmark, Denmark
View Trial DetailsNCT07016958
Atrophy, Diabetes Mellitus
Istanbul, Turkey (Türkiye)
View Trial Details